On November 1st 2018, the UK government re-scheduled medical cannabis from a schedule 1 drug (absence of medical benefit) to a schedule 2 drug (allowed to be prescribed under certain conditions). This track explores the development of the UK market since then and how the industry is progressing by drawing on experiences from Canada, Israel and Continental Europe. 

In the age of internet-based medicine and E-Health, a panel of leading clinicians and entrepreneurs will also explore what impact technology has on medical cannabis and how innovation is driving new ways of measuring efficacy, patient-doctor interactions, and access to personalised medicines. 

With the NICE Guidelines on Cannabis based medicines set to be published on Nov 4th, don’t miss this excellent opportunity to interact with some of the leading international medicinal cannabis experts! 

Our session will start with a keynote of Prof Dedi Meiri on the GIANT stage and will be followed by panels in a dedicated separate room. 

Speakers

Mr. Benjamin Lesegno

CMO & Co-founder

CELLEN

Prof. Michael Barnes

Chief Medical Officer

Lyphe Group

Dr. Christopher Blue

Physician

B Medical Center

Dr. Henry Fisher

Chief Scientific Officer

Hanway Associates

Jonathan Liebling

Co-founding Director

CPASS

Jaipaul Massey-Singh

Vice President, Strategy

CB2 Insights

Prof. David Meiri

Head, Laboratory of CancER bIOLOGY AND Cannabinoid Research

Technion, Israel

Dr. Dr Julie Moltke-Huitfeldt

Editor in Chief/Doctor

Getthedosage Ltd.

Dr. Chloe Sakal

Psychiatrist and Drug Science Clinical Director

Drug Science

Dr. Haggai Sharon

Clinician

Cellen

Basia Zieniewicz

Co-founding Director

CPASS

Curated by

Dr. Benjamin Viaris de Lesegno

Chief Medical Officer, Cellen

Dr Benjamin Viaris de Lesegno is the co-founder and Chief Medical Officer of Cellen, a Medical Cannabis e-Health company using technology such as big data, IoT and AI to provide tailored care to patients.

Eric Bystrom

Founder, Cellen

Eric is the Co-founder and CEO of Cellen, a E-Health company using technology to drive new ways of measuring efficacy, patient-doctor interactions, and access to personalized medicine for medical cannabis in the UK and Europe.